Articles

O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

BJH - volume 11, issue Abstract Book BHS, february 2020

N. Vandewalle , P. Vlummens MD, N. De Beule MD, PhD, S. Faict , I. Oudaert , dr. K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD, K. De Veirman

Read more

Targeted therapies in multiple myeloma: new antibodies and CAR-T cells

BJH - volume 9, issue Multiple Myeloma Special Edition, december 2018

A. Van De Velde MD, PhD, M. Timmers , P. Vlummens MD, S. Anguille MD, PhD

SUMMARY

New therapeutic antibodies and T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in haematologic malignancies and multiple myeloma (MM). Various designs, manufacturing processes, and study populations, among other variables, have been tested and reported in clinical trials in MM. Here, we review and compare ongoing trials and the results of the reported clinical trials. We also discuss the outlook for CAR-T cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all haematologic malignancies.

Read more

Is it possible to predict who may never need treatment for B-CLL?

BJH - volume 9, issue 3, june 2018

V. Galle MD, P. Vlummens MD, F. Offner MD, PhD

SUMMARY

Chronic lymphocytic leukaemia has a very heterogeneous disease evolution. Prognostic factors of B-CLL overall survival have been extensively studied. However, much less is known about prognostic factors that can identify patients who will never develop an indication for treatment, at the time of their initial diagnosis. In this study we give an overview of variables that have a predictive value for treatment free survival. Subsequently, we try to develop a novel prognostic index, to address the question ‘who will never need treatment for B-CLL?’.

(BELG J HEMATOL 2018;9(3):124–9)

Read more

P30 Severe pancytopenia as presenting feature in newly diagnosed multiple myeloma (NDMM): a rare presentation

BJH - 2018, issue Abstract Book BHS, february 2018

C. De Vriendt , S. Kennes MD, M. Hofmans MD, PhD, P. Vlummens MD

Read more

P45 Donor cell derived deletion 7q occurring after allogeneic stem cell transplantation: a case report

BJH - 2018, issue Abstract Book BHS, february 2018

dr. A. Delie MD, P. Vlummens MD, N. Van Roy PhD, F. Offner MD, PhD, T. Kerre MD, PhD

Read more

PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?

BJH - 2018, issue Abstract Book BHS, february 2018

V. Galle MD, P. Vlummens MD, F. Offner MD, PhD

Read more

P11 Blastic plasmacytoid dendritic cell neoplasm with skin, bone marrow and CNS involvement: a case report

BJH - 2018, issue Abstract Book BHS, february 2018

K. Imaeva , P. Vlummens MD, S. Verbeke , J. Philippé MD, PhD, I. Moors MD

Read more